Collection of Data and Samples From Healthy Donors for Use in Translational Research

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-12-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Increased numbers of white blood cells called eosinophils can cause disease. To investigate this disease, researchers need blood, urine, sputum, stool, cerebrospinal fluid, skin and/or bone marrow samples to compare to samples from patients with this problem. Some of the samples will be used for genetic testing or future research.

This study will last for about 10 years and will include a maximum of 50 paid volunteers ages 18 to 65.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects

NCT04408950

Immunodeficiency

COMPLETED

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

NCT00001582

T-cell Lymphoma B-Cell Lymphoma ATL +1 more

COMPLETED

Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors

NCT03114566

Healthy

TERMINATED

Safety/Efficacy of a Vaccine Prepared From Dendritic Cells Combined With Tumor Cells to Treat Advanced Kidney Cancer

NCT00050323

Carcinoma, Renal Cell

COMPLETED PHASE1/PHASE2

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

NCT00625755

Renal Cell Carcinoma

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This protocol is designed to provide data and samples from paid volunteers for use in translational studies of eosinophilia and parasitic diseases. Donors meeting standard normal donor eligibility criteria will be recruited to undergo research procedures (infrared thermography and/or esophageal string test) and/or to donate blood, body fluid and/or tissue samples obtained using conventional techniques. The investigational nature of the studies in which their data and/or samples will be used, as well as the risks and benefits of the procedures, will be explained to all volunteers, and a signed informed consent document will be obtained. Volunteers will be compensated according to an established schedule based on the duration and discomfort of the donation. Samples provided through this protocol will be used solely for in vitro research and will be assigned a unique product number. The study investigators listed on this protocol will serve as the custodians of the code that links the product with a donor s identity. The nature of the in vitro studies in which the data and specimens collected in this study will be used is not the subject of this protocol and will be described in general terms only, since it involves several IRB-approved LPD protocols. Because some of these protocols require normal controls without a history of asthma or allergic disease, all subjects will undergo a standardized allergy/asthma history at enrollment. Serum immunoglobulin levels and a basic RAST panel may be performed on sera from some normal donors, and some normal donors may be asked to undergo pulmonary function testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteer

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

and/or sputum donation)

* ability to sign informed consent
* healthy male or female
* 18-85 years of age

* ability to sign informed consent
* healthy, male or female
* 18-65 years of age
* willingness to provide concurrent blood sample

Exclusion Criteria

and/or sputum donation)

* pregnancy
* weight \<110 pounds
* history of heart, lung, kidney disease, chronic anemia or bleeding disorders

Eligibility for tissue biopsy donation (other than skin) will be determined by the protocol under which the procedure is performed and the physician performing the procedure.

Eligibility criteria for volunteer bone marrow, skin and cerebrospinal fluid donation are more stringent than those for other specimen donations to minimize risk of procedure complications and maximize utility of specimens for study:

* a known bleeding disorder, low platelets (\<100k) or taking medications that interfere with blood clotting, such as aspirin, non-steroidal anti-inflammatory agents or warfarin
* anemia (hemoglobin less than 12.3 mg/dL)
* evidence of an immune deficiency, such as HIV infection or cancer
* pregnancy
* taking a medication that affects the immune response within the past month, including oral, intravenous, or injectable steroids
* allergic to xylocaine
* have taken an investigational drug in the last 6 months
* any other medical condition that the investigator feels puts the participant at too high a risk for participation

* warfarin and/or heparin treatment will not be stopped so that a subject can participate in this protocol. If warfarin or heparin was recently discontinued, a subject can be enrolled, but no bone marrow procedures will be performed until the PT is \< 15.5 seconds and the PTT is within normal range. For other agents that interfere with blood clotting without prolonging the PT, a 7- day washout period will be required before bone marrow sampling, skin biopsy or lumbar puncture.

-Previous diagnosis of central nervous system pathology (including tumors,

inflammatory conditions, infection, seizure disorder, spina bifida)

* History of spinal surgery with hardware placement
* History of any spinal surgery or injections of the lumbosacral spine
* Headache on the day of donation

-History of keloid or abnormal scar formation

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes